Marcello Candelli, Enrico C. Nista, Emilia Carloni, Giulia Pignataro, Maria Assonta Zocco, Alossia Cazzato, Cristiana Di Campli, Lucia Fini, Giovanni Gasbarrini and Antonio Gasbarrini Pages 375 - 384 ( 10 )
Helicobacter pylori infection has been indicated as the main pathogenic factor in the development of chronic gastritis, peptic ulcer disease, and gastric malignancies. Although the vast majority of infected subjects do not carry but a mild, asymptomatic gastritis, still there are some cases in which the eradication of the infection appears mandatory. This review addresses current anti-Helicobacter regimens and pharmacological resources, and highlights the pros and cons of each of them, according to the most recent and reliable clinical trials. Also, basic recommendations are given, regarding treatment choice in the event of the failure of a first or second line eradicating strategy, and about the implementation of standard regimens with newer antibacterial devices as probiotics.
H. pylori Infection,pathogenic factor,anti-Helicobacter regimens,asymptomatic gastritis
, , , , , , , , , Professor of Internal Medicine, Catholic University of Rome, Largo A Gemelli 8, 00168 Rome, Italy.